Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor–Positive Advanced Breast Cancer (EVERMET)

Abstract

The impact of on-treatment glycemia on the efficacy of everolimus-exemestane therapy in patients with HR⁺/HER2^- aBC depends on baseline glycemia. This study lays the foundations for investigating novel therapeutic approaches to target the glucose/insulin axis in combination with PI3K/AKT/mTORC1 inhibitors in patients with HR⁺/HER2^- aBC.